Rajita Menon

Among adults with laboratory-confirmed Clostridioides difficile infection (CDI) with 1 or more prior CDI episodes in the last 6 months and those with primary CDI at high risk for recurrence, high-dose VE303 prevented recurrent CDI vs placebo. ja.ma/3ohZHVZ #ECCMID2023

Consistent large-scale cGMP production of defined bacterial consortia will be critical for late stage clinical studies and commercialization of #microbiome therapies. Today we launched a state-of-the-art manufacturing facility to bridge this gap bit.ly/39XUpZd

Recently we published Ph 1 results in healthy volunteers of our defined bacterial consortium VE303 that informed rational dose selection. Today, at #DDW22, we present data showing that VE303 is efficacious in Ph 2 and that higher dose ➡️ better colonization ➡️ higher activity

We are presenting key data on our defined consortia VE303 (C. difficile) and VE202 (IBD) programs at #DDW2022, which is taking place from May 21-23. These include three oral presentations: ...

Today we published at @cellhostmicrobe the results of a Phase 1 study of @vedantabio‘s lead candidate VE303 (for C. difficile infection), with a focus one studying pharmacokinetics (PK) and pharmacodynamics (PD) of this defined bacterial consortium. bit.ly/3KE85Wo🧵 /1